
Biocartesian
Biocartesian is a YC Summer 2024 (S24) company. Based in San Francisco, CA, USA. Team of 2.
About Biocartesian
Summary
Biocartesian builds optical pooled screening technology for drug discovery researchers who need to link genetic perturbations to cell-level phenotypes at scale. Its proprietary ARADIA platform sequences genomic DNA targets directly inside cells, letting researchers run pooled CRISPR, CAR, UTR, or barcode screens while simultaneously capturing microscopy-based readouts, including morphology, protein, RNA, and live-cell assays, from each individual cell. This replaces conventional approaches that require separating genetic readout from imaging, losing the spatial and phenotypic context that explains how a perturbation acts.
Go-to-market
Biocartesian sells to cell biology and drug discovery teams in biopharma and academic research, offering both the ARADIA technology and screening services, with entry through direct meetings booked on its site.
From the Y Combinator listing
Converting biology into digital molecular maps
Finding new cures requires seeing what and where the abnormal molecules are in a diseased tissue, but current tools see less than 1% of those molecules. Biocartesian combines microscopy and new chemistries to see 50X more, offering unprecedented insights into disease biology and new therapies.
Facts
- Healthcare / Healthcare -> Drug Discovery and Delivery
- San Francisco, CA, USA
- 2
- Active
- Early
Founders (2)
- Ian Dardani
- Jess Li
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works